Compounds > 2,7-diaminomitosene
Page last updated: 2024-12-05

2,7-diaminomitosene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID4210
CHEMBL ID85852
MeSH IDM0158998

Synonyms (7)

Synonym
CHEMBL85852
78598-43-3
(2,6-diamino-7-methyl-5,8-dioxo-2,3-dihydro-1h-pyrrolo[1,2-a]indol-4-yl)methyl carbamate
2,7-diaminomitosene
1h-pyrrolo(1,2-a)indole-5,8-dione, 2,7-diamino-9-(((aminocarbonyl)oxy)methyl)-2,3-dihydro-6-methyl-
DTXSID50999874
(2,7-diamino-6-methyl-5,8-dioxo-2,3,5,8-tetrahydro-1h-pyrrolo[1,2-a]indol-9-yl)methyl hydrogen carbonimidate

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Microspheres produced a tumour pharmacokinetic profile of steady state drug levels, avoiding the much higher early peak (20."( Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity. Implications for the drugs' in vivo mechanism of action.
Allan, L; Cummings, J; Smyth, JF, 1994)		0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID54275Ability to reverse DNA double-strand breaks induced by ionozing radiation on exposure for 1 hr at a concentration of 10 ug/mL1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID95059Survival of L-1210 leukemia cells upon exposure to the compound for 1 hr at a concentration of 500ug/mL, measured in colony forming units.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID54278Ability to reverse DNA double-strand breaks induced by ionozing radiation on exposure for 1 hr at a concentration of 500 ug/mL1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID54277Ability to reverse DNA double-strand breaks induced by ionozing radiation on exposure for 1 hr at a concentration of 250 ug/mL1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID54274Ability to reverse DNA double-strand breaks induced by ionozing radiation on exposure for 1 hr at a concentration of 100 ug/mL1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID54279Ability to reverse DNA double-strand breaks induced by ionozing radiation on exposure for 1 hr at a concentration of 50 ug/mL1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID95060Survival of L-1210 leukemia cells upon exposure to the compound for 1 hr at a concentration of 50ug/mL, measured in colony forming units.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID95056Survival of L-1210 leukemia cells upon exposure to the compound for 1 hr at a concentration of 10ug/mL, measured in colony forming units.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID95058Survival of L-1210 leukemia cells upon exposure to the compound for 1 hr at a concentration of 250ug/mL, measured in colony forming units.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
AID95055Survival of L-1210 leukemia cells upon exposure to the compound for 1 hr at a concentration of 100ug/mL, measured in colony forming units.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Alkylation of DNA by C-10 of 2,7-diaminomitosene.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.67)18.7374
1990's8 (53.33)18.2507
2000's5 (33.33)29.6817
2010's1 (6.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.39 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methyl methanesulfonate
[no description available]		1.9710methanesulfonate esteralkylating agent;
apoptosis inducer;
carcinogenic agent;
genotoxin;
mutagen
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		3.79110mitomycinalkylating agent;
antineoplastic agent
quinone methide
quinone methide: intermediate in eumelanin biosynthesis; structure given in first source. quinomethane : A methylidenecyclohexadienone, formally derived from a benzoquinone by replacement of one of the quinone oxygens by a methylidene group.		1.9810quinomethane
mitosene
mitosene: structure given in first source		2.3820
10-decarbamoylmitomycin c
10-decarbamoylmitomycin C: RN given refers to the (1aS-(1aalpha,8beta,8aalpha,8balpha))-isomer; RN for cpd without isomeric designation not available 4/91		2.4120
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		1.9810organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
oligonucleotides
[no description available]		2.0210
dicumarol
Dicumarol: An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.		210hydroxycoumarinanticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist
deoxyguanosine
[no description available]		7.4220purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
guanine
[no description available]		7102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		02.3820
Anoxemia
[description not available]		02.0110
Breast Cancer
[description not available]		02.0110
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.0110
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0110
Experimental Mammary Neoplasms
[description not available]		02.3920
Adenocarcinoma, Basal Cell
[description not available]		01.9810
Cancer of Colon
[description not available]		01.9810
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9810
Colonic Neoplasms
Tumors or cancer of the COLON.		01.9810
Animal Mammary Carcinoma
[description not available]		02.420
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		01.9710